Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Biol Ther. 2011 Jan;11(1):41-53. doi: 10.1517/14712598.2011.540235. Epub 2010 Nov 29.

Stem cell-based strategies for the treatment of type 1 diabetes mellitus.

Author information

1
University of Louisville, Institute for Cellular Therapeutics, Louisville, KY 40202-1760, USA.

Abstract

IMPORTANCE OF THE FIELD:

β-Cell regeneration and β-cell preservation are two promising therapeutic approaches for the management of patients with type 1 diabetes (T1D). Stem cell-based strategies to address the problems of shortage in β cells, autoimmune and alloimmune responses have become an area of intense study.

AREAS COVERED IN THIS REVIEW:

This review focuses on the progress that has been made in obtaining functional, insulin-producing cells from various types of stem/progenitor cells, including the current knowledge on the immunomodulatory roles of hematopoietic stem cell and multipotent stromal cell in the therapies for T1D.

WHAT THE READER WILL GAIN:

A broad overview of recent advancements in this field is provided. The hurdles that remain in the path of using stem cell-based strategies for the treatment of T1D and possible approaches to overcome these challenges are discussed.

TAKE HOME MESSAGE:

Stem cell-based strategies hold great promise for the treatment of T1D. In spite of the progress that has been made over the last decade, a number of obstacles and concerns need to be cleared before widespread clinical application is possible. In particular, the mechanism of ESC and iPSC-derived β-cell maturation in vivo is poorly understood.

PMID:
21110785
PMCID:
PMC3004481
DOI:
10.1517/14712598.2011.540235
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center